FDA issues neuropathy warning on fluoroquinolones

被引：0

|

作者：

不详

机构：

来源：

FORMULARY | 2013年 / 48卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：305 / 305

页数：1

相关论文

共 50 条

[21] Evaluation of FDA Boxed Warning on Prescribing Patterns of Fluoroquinolones for Uncomplicated Urinary Tract Infections
Cowart, Kevin
Worley, Marylee
El Rouby, Nihal
Sando, Karen
[J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (12) : 1192 - 1199
[22] FDA issues warning on use of triCitrasol as a dialysis catheter anticoagulant
不详
[J]. DIALYSIS & TRANSPLANTATION, 2000, 29 (06) : 310 - 310
[23] FDA Issues Warning Letters About Claims Regarding Lipodissolve
不详
[J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (07) : 874 - 874
[24] Fluoroquinolones and Peripheral Neuropathy
不详
[J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1429): : 89 - 90
[25] FDA issues warning that paroxetine may increase the risk of birth defects
Wong, S
[J]. CNS SPECTRUMS, 2005, 10 (11) : 858 - 858
[26] US FDA issues warning against unapproved stem cell therapy
[J]. Reactions Weekly, 2018, 1684 (1) : 1 - 1
[27] FDA issues warning letters about unapproved eye disorder therapies
[J]. Reactions Weekly, 2023, 1975 (1) : 6 - 6
[28] FDA strengthens warnings for fluoroquinolones
[J]. Reactions Weekly, 2018, 1711 (1) : 1 - 1
[29] Evaluating the Effects of a FDA Boxed Warning on Adverse Event Reporting: Is There a Difference in the Rate of Reporting of Tendon-Related Adverse Events Associated with the Use of Fluoroquinolones after a FDA Boxed Warning?
Olsen, Axel
Mease, Mary
Hall, John R.
Gemmen, Eric
Garvert, William
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S136 - S136
[30] US FDA issues PML warning after Tecfidera-related death
[J]. Reactions Weekly, 2014, 1530 (1) : 5 - 5

← 1 2 3 4 5 →